Alexander C Schmidt
Overview
Explore the profile of Alexander C Schmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
861
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Churchyard G, Houben R, Fielding K, Fiore-Gartland A, Esmail H, Grant A, et al.
Lancet Microbe
. 2024 Jul;
5(10):100895.
PMID: 38964359
Tuberculosis is a leading cause of death from an infectious agent globally. Infectious subclinical tuberculosis accounts for almost half of all tuberculosis cases in national tuberculosis prevalence surveys, and possibly...
2.
Mui W, Parekh F, Tseng A, Toro J, Craig T, Ndugga M, et al.
PLOS Glob Public Health
. 2023 Nov;
3(11):e0002544.
PMID: 37939024
An efficacious tuberculosis (TB) vaccine is critical to reducing the global burden of TB. TB vaccine trials require the identification of multiple sites globally that have both a high incidence...
3.
Nemes E, Fiore-Gartland A, Boggiano C, Coccia M, DSouza P, Gilbert P, et al.
Vaccine Insights
. 2023 Apr;
1(3):165-181.
PMID: 37091190
Immunization strategies against tuberculosis (TB) that confer better protection than neonatal vaccination with the 101-year-old Bacille Calmette-Guerin (BCG) are urgently needed to control the epidemic, but clinical development is hampered...
4.
Karron R, Herbert K, Wanionek K, Schmidt A, Schaap-Nutt A, Collins P, et al.
J Pediatric Infect Dis Soc
. 2023 Jan;
12(3):173-176.
PMID: 36594442
We conducted a phase I clinical trial of the live-attenuated recombinant human parainfluenza virus type 2 (HPIV2) vaccine candidate rHPIV2-15C/948L/∆1724 sequentially in adults, HPIV2-seropositive children, and HPIV2-seronegative children, the target...
5.
Friberg H, Gargulak M, Kong A, Lin L, Martinez L, Schmidt A, et al.
NPJ Vaccines
. 2022 Nov;
7(1):132.
PMID: 36316335
The increasing global impact of dengue underscores the need for a dengue virus (DENV) vaccine. We assessed B-cell and T-cell responses following vaccination with four formulations of a tetravalent dengue...
6.
Miner M, Hatherill M, Mave V, Gray G, Nachman S, Read S, et al.
Lancet HIV
. 2022 Oct;
9(11):e791-e800.
PMID: 36240834
New tuberculosis vaccine candidates that are in the development pipeline need to be studied in people with HIV, who are at high risk of acquiring Mycobacterium tuberculosis infection and tuberculosis...
7.
Garcia-Basteiro A, White R, Tait D, Schmidt A, Rangaka M, Quaife M, et al.
Eur Respir Rev
. 2022 Jun;
31(164).
PMID: 35675923
Tuberculosis (TB) remains a leading infectious cause of death worldwide and the coronavirus disease 2019 pandemic has negatively impacted the global TB burden of disease indicators. If the targets of...
8.
Lin L, Lyke K, Koren M, Jarman R, Eckels K, Lepine E, et al.
Am J Trop Med Hyg
. 2020 Apr;
103(1):132-141.
PMID: 32342848
Dengue disease and its causative agents, the dengue viruses (DENV-1-4), cause high morbidity in tropical and subtropical regions. We evaluated three dosing regimens of the investigational tetravalent AS03-adjuvanted dengue-purified inactivated...
9.
Diaz C, Koren M, Lin L, Martinez L, Eckels K, Campos M, et al.
Am J Trop Med Hyg
. 2020 Mar;
102(5):951-954.
PMID: 32124728
Four formulations of an investigational tetravalent dengue purified inactivated vaccine, administered as two doses one month (M) apart, were previously shown to be immunogenic and well-tolerated up to M13 of...
10.
Dos Santos G, Nguyen B, Damaso S, Godderis L, Martinez-Gomez X, Eckermann T, et al.
Drug Saf
. 2019 Dec;
43(3):265-279.
PMID: 31884676
Introduction: Seasonal influenza causes numerous deaths worldwide each year. Annual vaccination for disease prevention is crucial. Seasonal vaccines are updated each year to closely match circulating strains. Objective: To comply...